Chung Wu Investment Group LLC Invests $29,000 in United Therapeutics Corporation $UTHR

Chung Wu Investment Group LLC purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 100 shares of the biotechnology company’s stock, valued at approximately $29,000.

A number of other institutional investors have also added to or reduced their stakes in UTHR. Two Sigma Investments LP increased its position in United Therapeutics by 3.0% during the 4th quarter. Two Sigma Investments LP now owns 1,773 shares of the biotechnology company’s stock worth $626,000 after purchasing an additional 52 shares in the last quarter. UMB Bank n.a. increased its position in United Therapeutics by 17.1% during the 1st quarter. UMB Bank n.a. now owns 1,289 shares of the biotechnology company’s stock worth $397,000 after purchasing an additional 188 shares in the last quarter. Farther Finance Advisors LLC increased its position in United Therapeutics by 20.3% during the 1st quarter. Farther Finance Advisors LLC now owns 456 shares of the biotechnology company’s stock worth $140,000 after purchasing an additional 77 shares in the last quarter. Signet Financial Management LLC increased its position in United Therapeutics by 0.7% during the 1st quarter. Signet Financial Management LLC now owns 10,895 shares of the biotechnology company’s stock worth $3,359,000 after purchasing an additional 79 shares in the last quarter. Finally, SG Americas Securities LLC increased its position in United Therapeutics by 210.9% during the 1st quarter. SG Americas Securities LLC now owns 10,085 shares of the biotechnology company’s stock worth $3,109,000 after purchasing an additional 6,841 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

UTHR has been the subject of a number of research analyst reports. Cantor Fitzgerald upped their price objective on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 10th. Wells Fargo & Company upped their price target on shares of United Therapeutics from $295.00 to $414.00 and gave the company an “equal weight” rating in a research report on Wednesday, September 3rd. Jefferies Financial Group raised their price target on shares of United Therapeutics from $432.00 to $564.00 and gave the company a “buy” rating in a research note on Tuesday, September 2nd. UBS Group raised their price target on shares of United Therapeutics from $560.00 to $580.00 and gave the company a “buy” rating in a research note on Monday, September 29th. Finally, HC Wainwright raised their price target on shares of United Therapeutics from $400.00 to $500.00 and gave the company a “buy” rating in a research note on Friday, September 5th. Ten equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and an average price target of $449.57.

Insider Activity

In other news, CEO Martine A. Rothblatt sold 4,000 shares of the stock in a transaction on Monday, October 6th. The shares were sold at an average price of $449.69, for a total transaction of $1,798,760.00. Following the completion of the sale, the chief executive officer directly owned 130 shares in the company, valued at $58,459.70. This represents a 96.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $436.60, for a total transaction of $4,802,600.00. Following the sale, the executive vice president owned 36,781 shares of the company’s stock, valued at approximately $16,058,584.60. This trade represents a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 242,435 shares of company stock valued at $95,152,242. 10.30% of the stock is owned by corporate insiders.

United Therapeutics Stock Performance

UTHR stock opened at $453.28 on Tuesday. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $455.26. The company has a fifty day moving average price of $359.42 and a 200-day moving average price of $320.03. The company has a market capitalization of $20.45 billion, a P/E ratio of 17.69, a PEG ratio of 6.91 and a beta of 0.66.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The firm had revenue of $798.60 million for the quarter, compared to analyst estimates of $802.13 million. During the same quarter last year, the company earned $5.85 earnings per share. The company’s quarterly revenue was up 11.7% compared to the same quarter last year. As a group, sell-side analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.